With $92M, Kivu sets out to make 'kinder, gentler' ADCs - Yahoo Finance

Retrieved on: 2024-10-27 14:05:13

Tags for this article:

Biotechnology

Antineoplastic drugs

Antibody-drug conjugate

Click the tags to see associated articles and topics

With $92M, Kivu sets out to make 'kinder, gentler' ADCs - Yahoo Finance. View article details on hiswai:

Summary

The article discusses Kivu Biosciences, a biopharma startup focusing on creating innovative antibody-drug conjugates (ADCs) to treat cancer. Supported by Synaffix technology, its goal is more precise and stable cancer drugs, reflecting biopharmaceutical advancements. Tags highlight biotechnology and antineoplastic drug development, echoing Kivu's relation to Lake Kivu's potential eruptions as a metaphor for managing ADC risks.

Article found on: finance.yahoo.com

View Original Article